Dear Colleagues,
In the past years the development of computer technologies and electronics has undergone significant changes. New products and services have begun to establish in different fields of the industry.
But how will the newly gained knowledge and the associated opportunities transfer to the conservative pharma industry? How will the manufacturing process itself, the supply chain as a whole or the patient usability of the product change under this influence?
Currently a change in thinking seems to be taking place in our industry, specifically with regards to the use of smart data, machine learning and wireless connectivity. It has become increasingly indispensable for companies to provide expertise in these areas. Simultaneously the technological advancements are reflected in novel regulatory guidelines, for example in the area of serialization. Additionally, digital platforms providing therapy support to patients are on the rise, involving wearables and connected drug delivery devices systems.
Yet technology alone is not sufficient – value is added only by implementing practical applications and solutions. Often this is only possible with a strong partner.
Beginning with an overview on serialization activities and feedback regarding the recent EU-initiative, regulatory considerations of the various applications within the wide field of the Internet of Health will be presented. This includes Cyber Security, Privacy, Data Transfer, Cloud Solutions, Integration within a Health Care System as well as aspects of Behavioral Science.
This one-day-workshop activity will also include an interactive group session where attendees can learn about the challenges patients are confronted with in different situations of their day-to-day use and how they can be better met by our industry.
We look forward to welcoming you online this Fall!
Sincerely,
The Workshop Lead,
Iain Simpson, Phillips Medisize – a Molex Company
Workshop Committee:
Iain Simpson, Phillips Medisize – A Molex Company - Workshop Lead
Quentin Le Masne, Merck KGaA
Scott Mullen, Ascendis Pharma
Paul Upham, Roche/Genentech